220 related articles for article (PubMed ID: 18382459)
1. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis.
Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Jackson S; Ryder S; Cramp M; Stein K
Br J Cancer; 2008 Apr; 98(7):1166-75. PubMed ID: 18382459
[TBL] [Abstract][Full Text] [Related]
2. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms.
Parikh ND; Singal AG; Hutton DW; Tapper EB
Am J Gastroenterol; 2020 Oct; 115(10):1642-1649. PubMed ID: 32530829
[TBL] [Abstract][Full Text] [Related]
4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma surveillance based on the Australian Consensus Guidelines: a health economic modelling study.
Nguyen ALT; Si L; Lubel JS; Shackel N; Yee KC; Wilson M; Bradshaw J; Hardy K; Palmer AJ; Blizzard CL; de Graaff B
BMC Health Serv Res; 2023 Apr; 23(1):378. PubMed ID: 37076870
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness of anti-tumor associated antigen autoantibody screening for hepatocellular carcinoma in the population with chronic hepatitis B-related cirrhosis].
Zhang M; Li YG; Wang KY; Wang X; Dai LP; Wang P; Ye H; Shi JX; Yang XA; Zhang SX; Zhang JY
Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(32):2544-2551. PubMed ID: 34407581
[No Abstract] [Full Text] [Related]
8. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
[TBL] [Abstract][Full Text] [Related]
9. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis.
Arguedas MR; Chen VK; Eloubeidi MA; Fallon MB
Am J Gastroenterol; 2003 Mar; 98(3):679-90. PubMed ID: 12650806
[TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.
Patel D; Terrault NA; Yao FY; Bass NM; Ladabaum U
Clin Gastroenterol Hepatol; 2005 Jan; 3(1):75-84. PubMed ID: 15645408
[TBL] [Abstract][Full Text] [Related]
12. Cost-Utility Analysis of Non-Contrast Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance in Cirrhosis.
Decharatanachart P; Pan-Ngum W; Peeraphatdit T; Tanpowpong N; Tangkijvanich P; Treeprasertsuk S; Rerknimitr R; Chaiteerakij R
Gut Liver; 2024 Jan; 18(1):135-146. PubMed ID: 37560799
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances.
Nouso K; Tanaka H; Uematsu S; Shiraga K; Okamoto R; Onishi H; Nakamura S; Kobayashi Y; Araki Y; Aoki N; Shiratori Y
J Gastroenterol Hepatol; 2008 Mar; 23(3):437-44. PubMed ID: 17683496
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis.
Worland T; Harrison B; Delmenico L; Dowling D
J Gastrointest Cancer; 2018 Dec; 49(4):476-480. PubMed ID: 28920172
[TBL] [Abstract][Full Text] [Related]
15. Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study.
Uyei J; Taddei TH; Kaplan DE; Chapko M; Stevens ER; Braithwaite RS
PLoS One; 2019; 14(8):e0221614. PubMed ID: 31449554
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.
Lin OS; Keeffe EB; Sanders GD; Owens DK
Aliment Pharmacol Ther; 2004 Jun; 19(11):1159-72. PubMed ID: 15153169
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound elastography for fibrosis surveillance is cost effective in patients with chronic hepatitis C virus in the UK.
Canavan C; Eisenburg J; Meng L; Corey K; Hur C
Dig Dis Sci; 2013 Sep; 58(9):2691-704. PubMed ID: 23720196
[TBL] [Abstract][Full Text] [Related]
18. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis.
Nahon P; Najean M; Layese R; Zarca K; Segar LB; Cagnot C; Ganne-Carrié N; N'Kontchou G; Pol S; Chaffaut C; Carrat F; Ronot M; Audureau E; Durand-Zaleski I; ; ; ;
JHEP Rep; 2022 Jan; 4(1):100390. PubMed ID: 34977518
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis.
Sarasin FP; Giostra E; Hadengue A
Am J Med; 1996 Oct; 101(4):422-34. PubMed ID: 8873514
[TBL] [Abstract][Full Text] [Related]
20. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.
Bolondi L; Sofia S; Siringo S; Gaiani S; Casali A; Zironi G; Piscaglia F; Gramantieri L; Zanetti M; Sherman M
Gut; 2001 Feb; 48(2):251-9. PubMed ID: 11156649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
